Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | RARB | P10826 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352671 | 0.98 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL3096224 | 0.98 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL9850865 | 0.98 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL5692767 | 0.98 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL27637297 | 0.98 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL2828991 | 0.98 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL21551509 | 0.98 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL2923654 | 0.98 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| Methane SCHEMBL4112746 | 0.96 | NR5A1 (0.63) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| Ethane SCHEMBL4117624 | 0.96 | NR5A1 (0.63) | NR5A1LTA4HTP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109796325-A | A kind of preparation method of anidulafungin intermediate | 南京天越星生物技术有限公司 | 2019-05-24 | — | — | CN | claimed |
| CN-110437846-B | Fluorine substituted benzoxazole liquid crystal compound containing acetylene bond and preparation method thereof | 陕西师范大学 | 2022-02-25 | — | — | CN | disclosed |
| CN-110483407-A | N- methyl substituted benzimidazole liquid-crystal compounds containing acetylene bond and preparation method thereof | UNIV SHAANXI NORMAL | 2019-11-22 | — | — | CN | disclosed |
| CN-110483408-A | A kind of N- methyl substituted benzimidazole side fluorine liquid-crystal compounds of big birefringence and preparation method thereof | UNIV SHAANXI NORMAL | 2019-11-22 | — | — | CN | disclosed |
| CN-110483435-A | A kind of fluorine-containing benzoxazoles liquid-crystal compounds and its synthetic method of big birefringence | UNIV SHAANXI NORMAL | 2019-11-22 | — | — | CN | disclosed |
| CN-110483434-A | Big birefringence side fluorine benzoxazoles liquid-crystal compounds containing acetylene bond and preparation method thereof | UNIV SHAANXI NORMAL | 2019-11-22 | — | — | CN | disclosed |
| CN-110437846-A | Fluorine containing acetylene bond replaces benzoxazoles liquid-crystal compounds and preparation method thereof | UNIV SHAANXI NORMAL | 2019-11-12 | — | — | CN | disclosed |
| CN-109796325-A | A kind of preparation method of anidulafungin intermediate | 南京天越星生物技术有限公司 | 2019-05-24 | — | — | CN | disclosed |
| CN-109796325-A | A kind of preparation method of anidulafungin intermediate | 南京天越星生物技术有限公司 | 2019-05-24 | — | — | CN | disclosed |
| US-20160152654-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-06-02 | — | — | US | disclosed |
| US-5691349-A | ANTICHOLESTEROL AGENTS; ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 1997-11-25 | — | — | US | disclosed |
| EP-0654032-B1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LTD (GB) | 1997-10-15 | — | — | EP | disclosed |
| EP-0654032-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS. | ZENECA LTD (GB) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003451-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152654-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | NR5A1 2069/4885LTA4H 733/4885TP53 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.